RxDoctor Payments Data

Eric Zhou, MD

Internal Medicine · New York, NYNPI 1689674855

Payments from drug & device makers

$48,001in general payments, 2019–2025

Across 733 payments — averaging $65.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$29K
  • AstraZeneca$4K
  • Amgen$4K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Lilly USA, LLC$917
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$3,0006%
  • Speaking & faculty fees$21,18044%
  • Travel & lodging$7222%
  • Food & beverage$22,83048%
  • Education$2691%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,001 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$43,040
Medicare patients
55
Services billed
498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol522$338,204
VemlidyTenofovir Alafenamide204$287,169
VascepaIcosapent Ethyl642$264,872
JardianceEmpagliflozin287$212,601
TrulicityDulaglutide112$120,058
ProliaDenosumab71$118,651
JanuviaSitagliptin Phosphate158$102,848
SynjardyEmpagliflozin/Metformin Hcl144$95,272
XareltoRivaroxaban98$71,535
LinzessLinaclotide101$55,974
EliquisApixaban86$51,078
Breztri AerosphereBudesonide/Glycopyr/Formoterol82$50,950
TradjentaLinagliptin87$45,219
ShingrixVaricella-Zoster Ge/As01b/Pf202$30,321
AbrysvoRsv Vacc, Pref A And Pref B/Pf104$29,678

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$3,938$398,948646 claims
Boehringer IngelheimJardiance, Synjardy, Tradjenta, Synjardy Xr$1,191$371,929540 claims
GileadVemlidy$29,059$287,169204 claims
MerckJanuvia, Janumet$553$127,754182 claims
Lilly USA, LLCTrulicity$917$120,058112 claims
AmgenProlia$3,676$118,65171 claims
PfizerEliquis, Abrysvo$202$80,756190 claims
GSKShingrix, Arexvy, Trelegy Ellipta$1,331$72,708326 claims
Johnson & JohnsonXarelto$357$71,53598 claims
AbbVieLinzess$874$55,974101 claims
BayerKerendia$848$20,63526 claims
Astellas Pharma US IncMyrbetriq$186$19,84336 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →